OBLN vs. NSPR, CTCX, HSAQ, TMDIF, GBS, RVP, PETV, BTCY, NURO, and INVO
Should you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include InspireMD (NSPR), Carmell (CTCX), Health Sciences Acquisitions Co. 2 (HSAQ), Titan Medical (TMDIF), GBS (GBS), Retractable Technologies (RVP), PetVivo (PETV), Biotricity (BTCY), NeuroMetrix (NURO), and INVO Bioscience (INVO). These companies are all part of the "medical" sector.
Obalon Therapeutics vs. Its Competitors
Obalon Therapeutics (NASDAQ:OBLN) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.
InspireMD has a consensus price target of $4.50, suggesting a potential upside of 90.68%. Given InspireMD's stronger consensus rating and higher probable upside, analysts clearly believe InspireMD is more favorable than Obalon Therapeutics.
18.6% of Obalon Therapeutics shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 8.1% of Obalon Therapeutics shares are held by insiders. Comparatively, 34.1% of InspireMD shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, InspireMD had 4 more articles in the media than Obalon Therapeutics. MarketBeat recorded 4 mentions for InspireMD and 0 mentions for Obalon Therapeutics. InspireMD's average media sentiment score of 0.54 beat Obalon Therapeutics' score of 0.00 indicating that InspireMD is being referred to more favorably in the news media.
InspireMD has a net margin of -413.96% compared to Obalon Therapeutics' net margin of -776.76%. InspireMD's return on equity of -69.42% beat Obalon Therapeutics' return on equity.
Obalon Therapeutics has higher earnings, but lower revenue than InspireMD.
Obalon Therapeutics has a beta of -1.23, suggesting that its share price is 223% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.
Summary
InspireMD beats Obalon Therapeutics on 12 of the 15 factors compared between the two stocks.
Get Obalon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OBLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Obalon Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:OBLN) was last updated on 7/12/2025 by MarketBeat.com Staff
